doi: 10.1161/hs1201.100392
(Stroke. 2001;32:2882.)
© 2001 American Heart Association, Inc.
Original Contributions |
Joint Effect of the APOE Gene and Midlife Systolic Blood Pressure on Late-Life Cognitive Impairment
The Honolulu-Asia Aging Study
From the Epidemiology, Demography and Biometry Program, National Institute on Aging, National Institutes of Health, Bethesda, Md (R.P., R.J.H., L.J.L.), and the Pacific Health Research Institute (L.R.W., H.P., K.M.) and Department of Veteran’s Affairs (G.W.R.), Honolulu, Hawaii.
Correspondence to R. Peila, MS, EDBP/NIA/NIH, Gateway Bldg 3C-309, 7201 Wisconsin Ave, Bethesda, MD 20892. E-mail peilar{at}mail.nih.gov
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferencesHigh Blood Pressure and...References |
|---|
Background and Purpose— The aim of this study was to explore the joint effect of the APOE
4 allele and midlife systolic blood pressure (SBP) on the risk for poor cognitive function in late life.
Methods— The study includes 3605 surviving members of the cohort of the Japanese-American men followed prospectively over 26 years (1965–1991) as a part of the Honolulu Heart Program. In 1965 men were aged 45 to 68 years and were living in the island of Oahu, Hawaii. For this study the sample was divided into 4 categories: normal SBP (<160 mm Hg)/No 4, as the reference category; normal SBP/4; high SBP/no 4; high SBP/4. The relative risk (RR) of late-life intermediate and poor cognitive function relative to good function was measured by the Cognitive Abilities Screening Instrument (CASI) test.
Results— After adjusting for age, education, smoking, alcohol use, and body mass index, the RR for poor cognitive function (CASI <74) compared with good cognitive function (CASI 
82) in never-treated subjects was 1.3 (95% CI 0.9 to 1.9) for the normal SBP/4 category, 2.6 (0.7 to 10.0) for the high SBP/no 4, and 13.0 (1.9 to 83.8) for the high SBP/4. Adjustment for diabetes, prevalent stroke, coronary disease, and ankle-brachial index reduced the RR of poor cognition by 25.5% (RR 13.0 to 10.8) in those with both risk factors. In the treated group, the RR was 1.9 (0.7 to 4.5) for those with both risk factors.
Conclusions— The results suggest that midlife high SBP has a stronger adverse effect on cognitive function in persons with higher genetic susceptibility, but this effect may be modified by antihypertensive treatment.
Key Words: blood pressure • cognition • genetics
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferencesHigh Blood Pressure and...References |
|---|
Cognitive impairment is common among the elderly and can be an early symptom of dementia. Previous studies suggest that high BP levels increase the risk for late-life cognitive impairment1 and dementia.2 This association may be modified by antihypertensive medication.1,3
To date, the apolipoprotein E (APOE) gene is the most consistently identified genetic risk factor for cognitive impairment and Alzheimer’s disease. The gene is characterized by 3 major polymorphic forms, 2, 3, and 4; 4 is associated with a higher risk of dementia and cognitive decline.4,5 A possible synergism of APOE with other risk factors, in particular cerebrovascular disease, has been reported,6–9 suggesting that individuals with the 4 allele and cerebrovascular disease have a higher risk for cognitive impairment than if the 2 factors act independently. Here, we examined the joint effect of APOE 4 allele and high midlife BP on the risk for cognitive impairment late in life. Data are from a cohort of Japanese-American men living in Hawaii, who have been followed since 1965, when they were middle aged.
See Editorial Comment, page 2888
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferencesHigh Blood Pressure and...References |
|---|
Study Population
The Honolulu Heart Program (HHP) is a longitudinal population-based study designed to investigate heart disease and stroke among Japanese-American men.10 The original sample included 8006 Japanese-American men born between 1900 and 1919 who were living on Oahu, Hawaii, at baseline.11 After the first examination (1965–1968), the men were followed and further examined in 1968–1970 (examination 2) and again in 1971–1974 (examination 3). At each examination, simple clinical measures were made and sociodemographic and medical conditions assessed. In 1991–1993, the Honolulu-Asia Aging Study (HAAS) was established, with the aim of investigating neurodegenerative diseases in this cohort.12,1 Subjects who survived up to the 1991 examination were younger (52.7 versus 57.0 years at baseline examination, P<0.001), more educated (7.8 versus 8.5 years, P=0.001), and had higher midlife SBP (140.6 versus 132.9 mm Hg, P=0.001). In 1991, 3734 men (80% of the surviving cohort) underwent a clinical examination including assessment of cognitive function. Compared with nonrespondents, participants had similar age but proportionately higher education and less missing data from 1 of the 3 midlife exams (95% versus 75% with complete data, P=0.001). All subjects were informed about the study objectives and signed an informed consent form. The study was approved by the Institutional Review Board of Kuakini Medical Center.
Cognitive Function
The Cognitive Abilities Screening Instrument (CASI) was used to evaluate the cognitive status. The CASI is a validated test used for cross-cultural epidemiological studies,13 and is a combination of the Hasegawa Dementia Scale,14 the Mini-Mental State Examination,15 and the Modified Mini-Mental State Examination.16 The CASI score ranges from 0 to 100. Because the CASI distribution was highly skewed, 3 levels of cognitive function were created: "good" (CASI 82; upper 70% of the sample), "intermediate" (CASI 74 to 82; 15%) and "poor" (CASI <74; lowest 15% of the sample).12 In this cohort, a CASI score of <82 corresponded to a sensitivity of dementia (as defined in the Diagnosis and Statistical Manual of Mental Disorders17) of 80% and a specificity of 77%. To improve the sensitivity of dementia, subjects with low scores (CASI <74) were sorted out from the others because they had a high probability of being demented. However, because the CASI is not a clinical diagnostic tool, we did not label it as such.
Blood Pressure
BP was measured in the 3 midlife HHP examinations. At each examination, BP values represent the mean of 3 measurements made 5 minutes apart on the left arm while the subject was seated. Standard sphygmomanometer and cuff were used. Diastolic BP (DBP) was recorded as the fifth phase. Mean midlife SBP and DBP were calculated by using all measurements made over the first 3 exams. As in a previous report,1 SBP was further categorized as high if it was 160 mm Hg in at least 2 of the 3 examinations. All other subjects were classified in the normal SBP group. Similar criteria were adopted for DBP: individuals were characterized as having high DBP if 2 of the 3 examination values were 95 mm Hg, or as normal otherwise.
Apolipoprotein E genotyping
Blood samples were drawn at the fourth examination, and APOE genotyping was obtained by standard DNA amplification and restriction isotyping18 in 3605 subjects. The 4 allele frequency in the sample was 9.5%, lower than that reported among whites but similar to that in other Japanese populations.19 Among 4 carriers, 2.2% were homozygotes (44) and 97.8% were heterozygotes (24, 34). The limited number of 4 homozygotes (n=16) did not allow for the evaluation of gene dose effect (noncarriers versus 4 heterozygotes versus 4 homozygotes). For analysis purposes, all 4 carriers were combined in the APOE 4 group.
Covariates and Confounders
Several variables were considered to be possible covariates or confounders. We controlled the analysis for age at the fourth examination, education, midlife body mass index, smoking, and alcohol intake. We used midlife values because they are less influenced by preclinical dementia status. Body mass index (in kilograms per meters squared) was calculated from participants’ height and weight at each examination and averaged. Self-reported smoking was assessed at exams 1 and 3 and categorized by pack-year of cigarette exposure (packs of cigarettes per year times years of smoking). Alcohol intake was reported at exams 1 and 3 and recorded as grams of alcohol per day. In the multivariate analysis, the variable was recorded as drinks per day (none, <1 drink [13.2 g], 1 to 2 drinks, and 3 drinks/d). History of diabetes was assessed on the basis of self-report of doctor’s diagnosis, or use of diabetes medications, or with fasting glucose level equal to 126 mg/dL or higher, or with 2-hour postload glucose equal to 200 mg/dL or higher.20 Coronary heart disease (CHD; myocardial infarct and angina) and stroke events were monitored from 1965 through the entire follow-up by continuous surveillance of hospital discharge and death records on Oahu. Ankle-brachial index (ABI) was measured at the fourth examination, and the values were dichotomized with a cutoff of 0.9; values below this point were interpreted as indicator of generalized atherosclerosis.21 History of antihypertensive treatment to lower BP was self-reported by the subjects from examination 1 to 3 and required presentation of medication vials at examination 4. Assessment of the duration of the antihypertensive treatment was performed during the 1991 examination. In the total sample, there were 2082 participants (57.8%) never treated with antihypertensive medication. Compared with the untreated, the treated group was younger (P=0.03), and, after adjusting for age, had a higher education level (10.6 versus 10.4 y P=0.03) and mean midlife systolic (125 versus 141 mm Hg, P<0.0001) and diastolic BPs (79 versus 88 mm Hg, P<0.0001), and included more individuals with ABI 
0.9 (P<0.0001), CHD (P<0.0001), and stroke (P<0.0001). Smoking and alcohol intake were similar between the 2 groups. APOE 4 allele frequency was different between the 2 groups, although not significantly.
Statistical Analysis
The cohort was divided into 4 categories22: normal SBP (NSBP)/no 4, used as the reference group; NSBP/4; high SBP (HSBP)/no 4; and HSBP/4. Similar groups for APOE 4 and DBP were created. However, because no association between 4, DBP, and cognitive impairment was observed, these data are not further discussed. Cohort characteristics were compared across the cognitive function groups and SBP/APOE categories with age- and education-adjusted general linear models for continuous variables and logistic regression models for binary outcomes. A description of sociodemographic and health-related characteristics by cognitive function categories has been previously published.1 Briefly, subjects with good cognitive function were younger, more educated, had higher ABI and a low prevalence of stroke (P<0.001), while CHD and antihypertensive treatment were similar among the 3 groups of cognitive function.
Logistic regression was used to calculate the estimated relative risk (RR) and the 95% CI of intermediate and poor cognition in relation to good cognition associated with APOE 4 and high SBP. Analysis was adjusted for potential confounders. The cross-product interaction term for APOE and SBP and the 3-way interaction term among APOE, SBP, and hypertension treatment were also tested.
Based on the results of previous studies, which showed a reduction of the risk of low cognitive function and dementia associated with antihypertensive treatment,1,23 we considered a priori antihypertensive medication as a possible effect modifier of the association of APOE 4, high SBP and cognitive impairment. Therefore, we performed a stratified analysis. First, we divided the cohort into 2 groups (untreated and treated) and we included all those who were treated before the assessment of cognitive function in the treated group. However, because some of the subjects were treated for only a short period of time, we repeated the analysis, including those who were treated for <3 years prior to 1991 in the untreated group (n=473). In addition, we checked whether the 2 reference categories (NSBP/no 4) in the treated and untreated strata had a similar risk for poor cognition. Therefore subjects receiving antihypertensive treatment in the reference category (NSBP/no 4) were tested for their risk of intermediate and poor cognitive function compared with the nontreated ones in the same category.
The stratified analyses were adjusted for age and education, smoking, alcohol and body mass index (model 1); and then for diabetes, prevalent stroke, CHD, and ABI (model 2). A value of P<0.05 was accepted as statistically significant. All tests were 2-tailed. SAS version 6.1224 and STATA version 6.025 were used to perform the statistical analysis.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferencesHigh Blood Pressure and...References |
|---|
General Analysis
In the total sample, 5.9% had a midlife SBP of
160 mm Hg. Participants in the NSBP/no 4 and NSBP/4 categories were younger and less likely to receive antihypertensive medication than those in the other groups (Table 1). Individuals with high SBP alone or with the 4 allele had a higher prevalence of CHD, stroke, and diabetes and an ABI of 0.9 compared with the other 2 groups.
|
4 Status and Midlife High SBP Categories
In the total sample, the HSBP/no 4 category had an increased risk of poor cognitive function compared with the reference group (Table 2). In the HSBP/4 category, the estimated RR point estimate for poor cognitive function was slightly higher than expected if the 2 risks were added independently (1.3+2.1-1.0 [baseline risk]=2.4). The analysis was adjusted for age, education, antihypertensive treatment, and duration of the treatment. The 4 and HSBP interaction term was not significant (P=0.62); however, the 3-way 4 allele, HSBP, and antihypertensive treatment interaction term reached borderline significance (P=0.09).
|
Untreated Group
In the NSBP/no 4 group, those who were treated with antihypertensive medication did not have a different risk of intermediate and poor cognitive function compared with those untreated (age- and education-adjusted RR 1.2 [95% CI 0.9 to 1.4] and RR 0.9 [0.7 to 1.2, respectively]), suggesting that the baseline risk of low cognition for both groups (untreated and treated) was similar.
In the untreated group, the RR of intermediate cognitive function was significantly higher only for 4 allele carriers (RR 1.4, P=0.025; Table 3). The RR of poor cognition was 13.0 (P=0.009) in the HSBP/4 category. Adjustment for diabetes, CHD, stroke, and ABI reduced the RR of poor cognition by 17.0% (RR 13.0 to 10.8) for those with both high SBP and 4 allele. Hypertension and APOE 4 alone were not significant. We then included in the untreated group those who were treated for <3 years before the cognitive function assessment. In this group, the RR for intermediate cognitive function was 1.4 (P=0.03) for HSBP/no 4, 1.9 (P=0.09) for NSBP/4, and 1.3 (P=0.70) for HSBP/4. The RR for poor cognitive function was 1.4 (P=0.04) for HSBP/no 4, 3.1 (P=0.001) for NSBP/4, and 7.4 (P<0.001) for HSBP/4. Adjustment for the other covariates slightly reduced the point estimates, but the magnitude and the direction of the association remained similar (data not shown).
|
Treated Group
In the treated group, the risk for intermediate and poor cognitive function was similar in all the BP and 4 categories (Table 3). After removing from this group those who were treated only for the last 3 years before cognitive assessment, the results for both intermediate and poor cognitive function categories did not changed (data not shown).
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferencesHigh Blood Pressure and...References |
|---|
We found that among individuals never treated for hypertension, APOE
4 carriers with a midlife SBP of 160 mm Hg had a 10 times greater risk of late-life poor cognitive function than those without the APOE 4 allele and normal SBP. Among those treated with antihypertensive medication, individuals with both 4 and high SBP were not at significantly higher risk for poor cognition than those without the 2 risk factors.
The present study has several strengths. Data were collected prospectively from 1965 to 1991 on a large, population-based sample. BP was measured in midlife, when the level is less influenced by preclinical disease.2 However, there are some methodological issues that need to be accounted for when interpreting the results. The sample size of the HSBP/4 group in the untreated stratum was small, resulting in a wide CI around the estimate. This might explain why the interaction terms were not statistically significant. Possibly, only a few cases explain the results (type I error). The low prevalence of HSBP/4 individuals may be due to the lower frequency of the 4 allele in the Japanese population compared with other ethnic groups.19 More likely, it reflects a selective mortality, because both the 4 allele and HSBP are risk factors for CHD,26,27 which tends to occur at a younger age. Because genotyping was not done until the fourth examination, it was not possible to test this hypothesis using cohort members who died before 1991.
Several lines of evidence suggest that these findings are biologically plausible. An association of midlife high SBP and cognitive impairment has been shown, and multiple mechanisms linking the 2 traits have been proposed.1,28 High BP can damage large and small vessels that penetrate the brain. In addition, other atherosclerotic conditions related to high BP, including stroke, CHD, and peripheral artery disease, alter cerebral flow autoregulation.29,30 As consequence, transitory conditions of cerebral hypoxia/ischemia can occur, creating impaired cerebral perfusion and asymptomatic depression of oxygenation. Ischemia-related injuries can ultimately lead to clinical and subclinical brain damage, including lacunes and white matter abnormalities on MRI.31 APOE is hypothesized to play a central role in the response to neuronal injury by maintaining the integrity of the microtubules and redistributing lipids to regenerating neuronal axons.32 APOE-deficient mice have shown twice as much ischemic neuronal damage as wild-type controls after ischemic episodes.33 This neuroprotective function is highly allele specific: APOE 3 seems to promote the repair process and APOE 4 to retard it both in vitro and in vivo.34–37 It is possible that the effect of APOE on cognition is partially due to its modifying the damage created by hypertension. Under this hypothesis, the impact of the hypertension would be much greater among APOE 4 carriers due to their limited capacity to repair neuronal damage. In vivo data indicate that APOE 4 transgenic mice are more susceptible to the effects of the focal and global ischemia compared with the APOE 3 transgenic mice.38,39 APOE 4 is also associated with a lower concentration of plasma apoE protein40 and increased level of cholesterol and atherosclerosis,41 which can interact with hypertension and worsen atherosclerotic conditions. Under specific conditions, hypertensive-induced APOE-deficient mice have shown an increased of atherosclerotic lesions compared with normotensive and wild-type controls.42 A previous study of dementia in this cohort showed that in this population of Japanese-American men, the risk for the vascular dementia was higher than in those of European ancestry,12 which suggests that in this population there may be a relatively greater vascular contribution to cognitive impairment than in other groups. The role of an atherosclerosis in the APOE 4–high SBP interaction is suggested by the reduction in the RR for poor cognitive function after adjusting for stroke, ABI, and CHD. Therefore, we could interpret model 2 of the analysis as an overadjusted model.
SBP and APOE 4 may also interact through the amyloid processing pathways. In an autopsy series based on this cohort, high SBP was associated with the presence of neurofibrillary tangles and neuritic plaques.43 4 is associated with a greater ß-amyloid deposition and neuritic plaque formation in demented and nondemented individuals.44 In vitro and in vivo data suggest that ß-amyloid has a vasoconstrictive effect on the cerebral microcirculation.45,46 This could increase BP levels and exacerbate the insult to the brain created by high SBP. However, given that the BP was measured in midlife, this would imply a very long period of amyloid toxicity.
To date, a limited number of observational studies have examined the interaction between vascular factors, the APOE gene, and cognitive impairment.6–9 Two studies have focused specifically on the APOE and BP relationship to cognitive decline. The Zutphen Study7 tested the risk of cognitive decline in community-dwelling elderly men and found a lower risk of cognitive decline in those with both APOE 4 and hypertension (SBP/DBP 140/95 mm Hg or use of antihypertensive medication) compared with those without hypertension. However, BP was measured in late age, concurrent with the first cognitive evaluation. Other studies suggest that concurrently measured BP does not accurately reflect long-term exposure because BP changes with treatment, comorbidity, and possibly incipient dementia.47 Only 1 study has examined the long-term effect of midlife BP and the APOE gene on cognitive function.9 The study showed that the 4 allele and midlife hypertension (SBP/DBP 140/90 mm Hg or use of antihypertensive medication) were each associated with a 10-year decline in a neuropsychological test (Digit Symbol Substitution) score, but their combined effect was not greater than expected. However, because the sample was small, the ability to see interactions was low. In addition, in the latter 2 studies, antihypertensive treatment was included as a part of the definition of hypertension.
In the current study, antihypertensive treatment was used as an effect modifier. We found no negative effects of the combination of APOE 4 and HSBP on cognitive function in the treated group. Because the baseline BP and the 4-associated RR were similar in both the treated and untreated groups, this suggests that the potential benefits of the antihypertensive medication may be mediated by a BP-lowering effect. Other studies suggest that antihypertensive treatment may be beneficial in reducing the risk for dementia. A recent study23 reported a lower incidence of dementia among individuals treated with antihypertensive medication than in untreated subjects; the effect was more evident for APOE 4 carriers. In addition, a randomized trial48 has suggested that antihypertensive treatment may provide some benefits in decreasing the risk for dementia.
However, we cannot rule out several alternative explanations for a difference in effect between the treated and untreated groups. For instance, there may have been selective mortality. Individuals treated with antihypertensive drugs had higher levels of stroke and CHD compared with untreated individuals, and it cannot be excluded that a subset of treated hypertensives at risk for cognitive impairment died prematurely. Although we adjusted for a number of sociodemographic and health-related variables, it is also possible that treated and untreated hypertensive individuals differed by other risk factors not included in the analysis. Ongoing randomized controlled trials on antihypertensive medication and incidence of dementia should be able to examine more fully an interaction with APOE.
In conclusion, this study evaluated the possible synergistic effect of APOE genotype and high midlife SBP on the risk of poor cognitive function among elderly men. The results suggest that the use of antihypertensive medication could potentially reduce this negative outcome, especially for individuals genetically predisposed to higher risk. As life expectancy has increased in the last century, more individuals will reach a very old age and will be at risk both for high SBP and cognitive impairment. If confirmed, the present results may have important preventive public health implications.
|
Acknowledgments |
|---|
This work was supported by National Institutes of Health National Institute on Aging contract N (N01-AG-4-2149) and National Heart, Lung, and Blood Institute contract N (N01-HC-05102).
Received January 13, 2001; revision received July 25, 2001; accepted October 3, 2001.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferencesHigh Blood Pressure and...References |
|---|
1. Launer LJ, Masaki K, Petrovich H, Foley D, and Havlik RJ. The association between midlife blood pressure and late-life cognitive function. JAMA. 1995; 274: 1846–1851.
2. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347: 1141–1145.[Medline] [Order article via Infotrieve]
3.
Guo Z, Fratiglioni L, Zhu L, Fasthom J, Winblad B, and Viitanen M. Occurrence and progression of dementia in a community poulation aged 75 years and older. Relationship of anitihypertensive medication use. Arch Neurol. 1999; 56: 991–996.
4.
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to ß-amlyoid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90: 1977–1981.
5.
Breitner JCS, Welsh KA. Genes and recent developments in the epidemiology of Alzheimer’s disease and related dementia. Epidemiol Rev. 1995; 17: 39–47.
6. Slooter AJ, van Duijn CM, Bots ML, Ott A, Breteler MB, De Voecht J, Wehnert A, de Knijff P, Havekes LM, Grobbee DE, Van Broeckhoven C, Hofman A, Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl. 1998; 53: 17–29.[Medline] [Order article via Infotrieve]
7.
Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein 4 allele, and cognitive decline in a community-based study of elderly men. Stroke. 1996; 27: 2230–2235.
8.
Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE 4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999; 282: 40–46.
9. Carmelli D, Swan GE, Reed T, Miller B, Wolf PA, Jarvik GP, Schellenberg GD. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology. 1998; 50: 1580–1585.[Abstract]
10.
Syme SL, Marmot MU, Kagan A, Kato H, Rhoads G. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: introduction. Am J Epidemiol. 1975; 102: 477–480.
11. Worth RM, Kagan A. Ascertainment of men of Japanese ancestry in Hawaii through World War II selective registration. J Chronic Dis. 1970; 23: 389–397.[Medline] [Order article via Infotrieve]
12.
White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, Rodriguez BL, Blanchette PL, Havlik RJ, Wergowske G, Chiu D, Foley DJ, Murdaugh C, Curb JD. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia Aging Study. JAMA. 1996; 276: 955–960.
13. Teng EL, Hasegawa k, Homma A, Imai Y, Larson E, Graves A, Sugimoto K, Yamaguchi T, Sasaki H, Chiu D, White LR. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological study studies of dementia. Int Psychogeriatr. 1994; 6: 45–58.[Medline] [Order article via Infotrieve]
14. Hasewaga K. The clinical assessment of dementia in the aged: a dementia screening scale for psychogeriatric patients.In: Bergener M, Leher U, Lang E, Schmitz-Scherzer R, eds. Aging in the Eighties and Beyond. New York, NY: Springer Publishing Co; 1983: 207–218.
15. Flostein MF, Folstein SE, McHugh PR. "Mini-Mental State"? A practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res. 1975; 12: 189–198.[Medline] [Order article via Infotrieve]
16. Teng EL, Chui HC. The Modified Mini-Mental State (3 MS) examination. J Clin Psychiatry. 1987; 48: 314–318.[Medline] [Order article via Infotrieve]
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised. 3rd ed. Washington, DC: American Psychiatric Association; 1987.
18. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with. Hha. Int J Lipid Res. 1990; 31: 545–548.
19. Hallman M, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, Utermann G. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet. 1991; 49: 338–349.[Medline] [Order article via Infotrieve]
20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20: 1183–1187.[Medline] [Order article via Infotrieve]
21.
Newman AB, Sutton-Tyrrell K, Vogt MT, Kuller LH. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index. JAMA. 1993; 270: 487–489.
22. Ottman R. An epidemiologic approach to gene-environment interaction. Genet Epidemiol. 1990; 7: 177–185.[Medline] [Order article via Infotrieve]
23.
Guo Z, Fratiglioni L, Viitanen M, Lannfelt L, Basum H, Fastbom J, Winblad B. Apolipoprotein E 4 allele and the incidence of Alzheimer’s disease among persons aged 75 years and older: variation by use of antihypertensive medication? Am J Epidemiol. 2001; 153: 225–231.
24. SAS/STAT User’s Guide, Release 6.12. Cary, NC: SAS Institute Inc; 1996.
25. STATA: Statistics/Data Analysis. College Station, Tex: Stata Corp; 1999.
26.
Lambert JC, Brousseau T, Defosse V, Evans A, Arveiler D, Ruidavets JB, Haas B, Cambou JP, Luc G, Ducimetiere P, Cambien F, Chartier-Harlin MC, Amouyel P. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations: the ECTIM study. Hum Mol Genet. 2000; 9: 57–61.
27. Hall WD. Risk reduction associated with lowering systolic blood pressure: review of clinical trial data. Am Heart J. 1999; 138: 225–230.[Medline] [Order article via Infotrieve]
28. Viitanen M, and Guo Z. Are cognitive function and blood pressure related? Drugs & Aging. 1997; 3: 165–169.
29. Stranggard S, Oleson J, Skluhoj E, Lassen NA. Autoregulation of brain circulation in severe arterial hypertension. BMJ. 1973; 1: 507–510.
30.
Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res. 1990; 66: 8–17.
31. Van Swieten JC, Geyskes OG, Derix MA, Peeck BM, Ramos LM, van Latum JC, van Gijn J. Hypertension in the elderly is associated with white matter lesions and cognitive decline. Ann Neurol. 1991; 30: 825–830.[Medline] [Order article via Infotrieve]
32. Handelmann GE, Boyles JK, Weisgraber KH, Mahley RW, Pitas RE. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J Lipid Res. 1992; 33: 1677–1688.[Abstract]
33. Horsburgh K, Kelly S, McCulloch J, Higgins GA, Roses AD, Nicoll JA. Increased neuronal damage in apolipoprotein E-deficient mice following global ischaemia. Neuroreport. 1999; 10: 837–841.[Medline] [Order article via Infotrieve]
34.
Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994; 264: 850–852.
35.
Bellosta S, Nathan BP, Orth M, Dong LM, Mahley RW, Pitas RE. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J Biol Chem. 1995; 270: 27063–27071.
36. Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM. Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. J Neurochem. 1999; 73: 2613–2616.[Medline] [Order article via Infotrieve]
37.
Buttini M, Orth M, Bellosta S, Akeefe H, Pitas RE, Wyss-Coray T, Mucke L, Mahley RW. Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration. J Neurosci. 1999; 19: 4867–4880.
38. Sheng H, Laskowitz DT, Bennett E, Schmechel DE, Bart RD, Saunders AM, Pearlstein RD, Roses AD, Warner DS. Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab. 1998; 18: 361–636.[Medline] [Order article via Infotrieve]
39. Horsburgh K, McCulloch J, Nilsen M, Roses AD, Nicoll JA. Increased neuronal damage and apoE immunoreactivity in human apolipoprotein E, E4 isoform-specific, transgenic mice after global cerebral ischaemia. Eur J Neurosci. 2000; 12: 4309–4317.[Medline] [Order article via Infotrieve]
40. Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 1988; 42: 104–112.[Medline] [Order article via Infotrieve]
41.
Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988; 8: 1–21.
42.
Weiss D, Kools JJ, Taylor R, Angiotensin II-induced hypertension accelerated the development of atherosclerosis in ApoE-deficient mice. Circulation. 2001; 103: 448–454.
43. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, Nelson J, Davis DG, Hardman J, Foley DJ, Launer LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS (Honolulu-Asia Aging Study). Neurobiol Aging. 2000; 21: 57–62.[Medline] [Order article via Infotrieve]
44. Sparks LD, Scheff SW, Liu H, Landers T, Danner F, Coyne CM, Hunsaker JCIII. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E3 allele: comparison to confirmed Alzheimer’s disease patients. J Neurol Sci. 1996; 138: 97–104.[Medline] [Order article via Infotrieve]
45. Crawford F, Suo Z, Fang C, Mullan M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp Neurol. 1998; 150: 159–168.[Medline] [Order article via Infotrieve]
46. Arendash GW, Su GC, Crawford FC, Bjugstad KB, Mullan M. Intravascular ß-amyloid infusion increases blood pressure: implications for a vasoactive role of ß-amyloid in the pathogenesis of Alzheimer’s disease. Neurosci Lett. 1999; 268: 17–20.[Medline] [Order article via Infotrieve]
47. Elias MF. Effects of chronic hypertension on cognitive functioning. Geriatrics. 1998; 53 (suppl 1): S49–S52.
48. Forette E, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Barbarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R, on behalf of the Syst-Eur Investigators. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998; 352: 1347–1351.[Medline] [Order article via Infotrieve]
Editorial Comment
The Honolulu-Asia Aging Study
|
High Blood Pressure and Apolipoprotein E4: A True Synergistic Effect on Late-Life Cognitive Function |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferencesHigh Blood Pressure and...References |
|---|
Apolipoprotein E4 (apoE4) allele was shown to be strongly associated with the familial and sporadic forms of Alzheimer’s disease. The apoE4 allele can affect the rate of progression of the disease, the extent of the neuronal cell loss, the accumulation of amyloid plaques, and total beta amyloid production in the brain of AD subjects.1 ApoE4 carrier subjects were also shown to exhibit poor reinnervation and compensatory plasticity in vulnerable brain areas.1,2 Actually, the role of apoE in the maintenance of synaptic integrity and plasticity is so central to brain physiology that the ability of a subject to recover from traumatic brain injuries is highly dependent on apoE4 allele copy number.1 The risk for boxers to develop dementia later in life is conditioned by the presence of the apoE4 allele. Actually, head injury had been considered one of the most reliable environmental risk factor for sporadic AD until it was formally demonstrated that it is the case only for apoE4 carrier subjects.3 ApoE4 is also considered a risk factor for vascular diseases, because it acts as a key modulator of cholesterol transport and homeostasis in periphery. Recently, 2 independent pivotal epidemiological studies examining the effect of the cholesterol-lowering drugs statins on the incidence of AD reported clear protective effects of these agents in a cohort of subjects with varying risk of vascular diseases.4,5 Altogether, these studies suggest a subtle interplay between cardiovascular genetic risk factors and protective agents that modulate the onset and progression of Alzheimer’s disease.
Similarly, the advent of antihypertensive treatment of high systolic blood pressure has certainly brought a significant advance to pharmacological disease prevention. Not only has long-term therapy with these agents revolutionized the prevention and the control of vascular diseases such as stroke, but recent clinical studies clearly indicate a potent reduction of the risk of developing cognitive impairment later in life and, in its extreme form, Alzheimer’s disease.
In the preceding article, Peila and colleagues report the results of a large observational study demonstrating a synergistic association between high systolic blood pressure and the presence of the apoE4 allele on late-life cognitive function in a large cohort of Japanese-American men living in Hawaii. These men have been followed prospectively since 1965, when they were middle aged. If this very important association turns out to be central to the etiopathology of memory disorders such as Alzheimer’s disease or vascular dementia, it could represent an important breakthrough in the search for a medication that could prevent or slow down cognitive impairment due to aging or dementia.
The interaction between high blood pressure in midlife and the apoE4 allele is certainly consistent with the notion of a clear-cut contribution of cardiovascular changes in the pathophysiology of both sporadic Alzheimer’s disease and vascular dementia. However, one must also be careful not to generalize the observation, as it has been shown recently that vascular cognitive impairment without dementia is the most common form of this disease among those aged 65 to 84 years.6
However, for the statistical association to be considered central in the onset of late-life cognitive deficit, we must have evidence of a plausible explanation for the preventive effect and/or a plausible alternative explanation for the statistical association to be ruled out.
One of the most interesting function of apoE in the central nervous system is its central role in the transport and recycling of cholesterol and fatty acids from dead or dying neurons to neurons undergoing terminal sprouting and synaptic remodeling.7 ApoE facilitates the mobilization and redistribution of key lipid molecules in response to damage and neurodegenerative changes in the brain. However, humans, in contrast to all other mammals, are expressing 3 distinct apoE isoforms: apoE2, apoE3, and apoE4. While humans exhibiting the apoE3 and apoE2 alleles appear to exhibit optimal regenerative capacity throughout the brain, subjects carrying 1 or 2 apoE4 alleles demonstrated drastic reduction in regenerative capacity.1,2 One of the obvious consequence of this situation is a marked deterioration of the reinnervation process, with impact on age of onset, age of progression, and recovery period following brain damage or chronic neurodegenerative disease.
Thus, one has to view the injured or diseased brain as a delicate balance between cell loss and compensatory remodeling of surviving neurons. In subjects carrying an apoE4 allele, the ability to remodel its neuronal circuits in response to damage and cell death is drastically reduced and the loss of function is somewhat exacerbated by the virtual absence of compensatory mechanisms. In this context, the report of Peila et al could be viewed as another excellent example of poor compensation in apoE4 carrier, in which the injuries this time are caused by elevated high blood pressure over the course of several years (even decades). This could easily translate into 2 distinct groups of subjects: one group, without the E4 allele (so-called non-E4 subjects), showing normal compensatory remodeling and relatively intact cognitive function at old age or a very late cognitive impairment, and the second group, the apoE4 carriers, exhibiting little or no plasticity in response to the HBP-related damage and a much earlier age of onset for the late-life cognitive impairment. This interpretation of the results is easy to test in the Peila cohort, as one of the central predictions would be the presence of a much higher incidence of the cognitive deficits in non-apoE4 subjects after the age of 80 years and a much earlier age of onset of the cognitive deficits in apoE4/4 subjects.
Centre for Studies in Aging
Douglas Hospital
McGill University
Verdun, Quebec, Canada
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferencesHigh Blood Pressure and...References |
|---|
1. Poirier J. Apolipoprotein E in animal models of brain injury and in Alzheimer’s disease. Trends Neurosci. 1994; 12: 525–530.
2.
Arendt T, Schindler C, Bruckner MK, Eschrich K, Gibl V, Zedlick D, Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer’s disease carrying apolipoprotein 4 allele. J Neurosci. 1997; 17: 516–529.
3.
Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Chun M, Tycko B, Shelanski M. Synergistic effect of traumatic head injury and apolipoprotein E4 in patients with Alzheimer’s disease. Neurology. 1995; 45: 555–557.
4.
Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer’s disease associated with 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors. Arch Neurol. 2000; 57: 1439–1443.
5. Jick H, Zornberg GL, Jick SS, Seshadry S, Drachman DA. Statins and Alzheimer’s disease. Lancet. 2000; 356: 1627–1631.[Medline] [Order article via Infotrieve]
6.
Rockwood K, Wentzel C, Hashinsky V. Prevalence and outcome of vascular cognitive impairment. Neurology. 2000; 54: 447–451.
7. Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, Poirier J. Neurobiology of apolipoproteins and their receptors in the CNS and in Azlheimer’s disease. Brain Res Rev. 1998; 27: 119–142.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  L. B. Hoffman, J. Schmeidler, G. T. Lesser, M. S. Beeri, D. P. Purohit, H. T. Grossman, and V. Haroutunian Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons Neurology, May 19, 2009; 72(20): 1720 - 1726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Sturman, C. F. M. de Leon, J. L. Bienias, M. C. Morris, R. S. Wilson, and D. A. Evans Body mass index and cognitive decline in a biracial community population Neurology, January 29, 2008; 70(5): 360 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D S KNOPMAN Cerebrovascular disease and dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S121 - S127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. de Frias, D. Bunce, A. Wahlin, R. Adolfsson, K. Sleegers, M. Cruts, C. Van Broeckhoven, and L.-G. Nilsson Cholesterol and Triglycerides Moderate the Effect of Apolipoprotein E on Memory Functioning in Older Adults J. Gerontol. B. Psychol. Sci. Soc. Sci., March 1, 2007; 62(2): P112 - P118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Staessen, T. Richart, and W. H. Birkenhager Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective With More Brain Hypertension, March 1, 2007; 49(3): 389 - 400. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hu, P. Bretsky, E. M. Crimmins, J. M. Guralnik, D. B. Reuben, and T. E. Seeman Association Between Serum Beta-Carotene Levels and Decline of Cognitive Function in High-Functioning Older Persons With or Without Apolipoprotein E 4 Alleles: MacArthur Studies of Successful Aging. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 616 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Knopman Dementia and Cerebrovascular Disease Mayo Clin. Proc., February 1, 2006; 81(2): 223 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jagust, D. Harvey, D. Mungas, and M. Haan Central Obesity and the Aging Brain Arch Neurol, October 1, 2005; 62(10): 1545 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Blair, A. R. Folsom, D. S. Knopman, M. S. Bray, T. H. Mosley, E. Boerwinkle, and for the Atherosclerosis Risk in Communities Study APOE genotype and cognitive decline in a middle-aged cohort Neurology, January 25, 2005; 64(2): 268 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Whitmer, S. Sidney, J. Selby, S. C. Johnston, and K. Yaffe Midlife cardiovascular risk factors and risk of dementia in late life Neurology, January 25, 2005; 64(2): 277 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gottlieb, A. L. DeStefano, D. J. Foley, E. Mignot, S. Redline, R. J. Givelber, and T. Young APOE {epsilon}4 is associated with obstructive sleep apnea/hypopnea: The Sleep Heart Health Study Neurology, August 24, 2004; 63(4): 664 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S.C. Korf, L. R. White, P. Scheltens, and L. J. Launer Midlife Blood Pressure and the Risk of Hippocampal Atrophy: The Honolulu Asia Aging Study Hypertension, July 1, 2004; 44(1): 29 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-E. de Leeuw, F. Richard, J. C. de Groot, C. M. van Duijn, A. Hofman, J. van Gijn, and M. M.B. Breteler Interaction Between Hypertension, apoE, and Cerebral White Matter Lesions Stroke, May 1, 2004; 35(5): 1057 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Roher, C. Esh, T. A. Kokjohn, W. Kalback, D. C. Luehrs, J. D. Seward, L. I. Sue, and T. G. Beach Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer's Disease Arterioscler. Thromb. Vasc. Biol., November 1, 2003; 23(11): 2055 - 2062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Qiu, B. Winblad, J. Fastbom, and L. Fratiglioni Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD Neurology, September 9, 2003; 61(5): 655 - 660. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||